PHENOTYPE LOCK
LIVE

Serial Number

97388990

Owner

Quell Therapeutics Limited

Attorney

Carlynn Beth Ferguson

Filing Date

Apr 29, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PHENOTYPE LOCK Trademark

Serial Number: 97388990

PHENOTYPE LOCK is a trademark filed by Quell Therapeutics Limited on April 29, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently pending registration.

Owner Contact Info

Quell Therapeutics Limited (4 trademarks)

3rd Floor, Translation & Innovation Hub
London W120BZ , GB

Entity Type: 99

Trademark Details

Filing Date

April 29, 2022

Registration Date

Not Registered

Published for Opposition

March 19, 2024

Goods & Services

Chemical and biological preparations for use in science and industry; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry

Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products

Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 23, 2026 EXRA
SOU EXTENSION 4 GRANTED
Apr 22, 2026 EX4G
SOU EXTENSION 4 FILED
Apr 22, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Apr 22, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 23, 2025 EXRA
SOU EXTENSION 3 GRANTED
Oct 23, 2025 EX3G
SOU EXTENSION 3 FILED
Oct 23, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 23, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 22, 2025 EXRA
SOU EXTENSION 2 GRANTED
Mar 21, 2025 EX2G
SOU EXTENSION 2 FILED
Mar 21, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 21, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jun 5, 2024 EX1G
SOU EXTENSION 1 FILED
Jun 5, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 5, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 14, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 19, 2024 NPUB
PUBLISHED FOR OPPOSITION
Mar 19, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 28, 2024 NONP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 28, 2024 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 15, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 15, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 15, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 15, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 15, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 1, 2023 GNFN
FINAL REFUSAL E-MAILED
Nov 1, 2023 GNFR
FINAL REFUSAL WRITTEN
Nov 1, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 1, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 31, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 31, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 15, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 15, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 15, 2023 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jul 21, 2023 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jul 11, 2023 PBCR
ELECTRONIC RECORD REVIEW COMPLETE
Jun 29, 2023 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jun 23, 2023 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 22, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 22, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 22, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 22, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 22, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 20, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 19, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 19, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 27, 2023 GNRN
NON-FINAL ACTION E-MAILED
Feb 27, 2023 GNRT
NON-FINAL ACTION WRITTEN
Feb 27, 2023 CNRT
ASSIGNED TO EXAMINER
Feb 16, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 4, 2022 NWOS
NEW APPLICATION ENTERED
May 3, 2022 NWAP